Abstract | During the past two decades, the paradigm for cancer treatment has evolved from relatively nonspecific cytotoxic agents to selective, mechanism-based therapeutics. Cancer chemotherapies were initially identified through screens for compounds that killed rapidly dividing cells. These drugs remain the backbone of current treatment, but they are limited by a narrow therapeutic index, significant toxicities and frequently acquired resistance. More recently, an improved understanding of cancer pathogenesis has given rise to new treatment options, including targeted agents and cancer immunotherapy. Targeted approaches aim to inhibit molecular pathways that are crucial for tumour growth and maintenance; whereas, immunotherapy endeavours to stimulate a host immune response that effectuates long-lived tumour destruction. Targeted therapies and cytotoxic agents also modulate immune responses, which raises the possibility that these treatment strategies might be effectively combined with immunotherapy to improve clinical outcomes. REVIEWS NATURE REVIEWS | CANCER VOLUME 12 | APRIL 2012 | 237 completed within a few months, the stimulated immune response can accomplish disease control for extended periods. A dynamic host response might also underlie the unusual pattern of clinical response seen with ipilimumab, in which prolonged periods of stable disease or even an initial period of tumour growth before stabilization are sometimes observed 9 . Additionally, immune responses with ipilimumab can display an increase in breadth over time, diversifying reactivity to multiple tumour-associated antigens. Notwithstanding these advantages, an important limitation of ipilimumab is the fairly small proportion of patients who achieve clinical responses. This deficiency may at least partly reflect the potent immunosuppressive effects of wellestablished tumours, particularly given that many cancers are detected at a late stage when bulky lesions are already present.
Targeted therapies act by blocking essential biochemical pathways or mutant proteins that are required for tumour cell growth and survival 1 . These drugs can arrest tumour progression and can induce striking regressions in molecularly defined subsets of patients. Indeed, the first small-molecule-targeted agent, the BCR-ABL kinase inhibitor imatinib, rapidly induced complete cytogenetic responses in 76% of patients with chronic myelogenous leukaemia 2 . Further research into the underlying genetic pathways driving tumour proliferation uncovered additional oncoproteins that are crucial for tumour maintenance, such as epidermal growth factor receptor (EGFR), BRAF, KIT, HER2 (also known as ERBB2 and neu) and anaplastic lymphoma kinase (ALK) 3 . Similar to imatinib, small-molecule inhibitors of these kinases have effectuated impressive tumour responses in selected patients, although regressions are commonly followed by the development of progressive disease owing to the emergence of drugresistant variants. Resistance usually involves secondary mutations within the targeted protein or compensatory changes within the targeted pathway that bypass the drugmediated inhibition. Accordingly, targeted therapies may elicit dramatic tumour regressions, but persistence is generally short-lived, limiting their overall clinical benefit.
In parallel to these advances in targeting oncogenic mechanisms, the recent successes of sipuleucel-T and ipilimumab in Phase III clinical trials have validated the principle that immunotherapy can also extend cancer patient survival 4 . Sipuleucel-T, which has recently been approved by the US Food and Drug Administration (FDA) for use in metastatic, castration-resistant prostate cancer, is an autologous dendritic cell (DC) vaccine that aims to stimulate T cells that are specific for prostatic acid phosphatase (PAP), a protein that is overexpressed in prostate carcinoma cells 5 . Although the precise basis of action for sipuleucel-T remains under study, treatment with this drug increases median survival by 4 months with minimal toxicity. Ipilimumab, an antibody that is specific for cytotoxic T lymphocyte-associated antigen 4 (CTLA4), blocks an important inhibitory signal for activated T cells, thereby bolstering T cell responses and potentiating tumour destruction 6 . Ipilimumab, which has recently been approved by the FDA for use as firstline or second-line therapy for patients with advanced melanoma, enhances overall survival compared with standard care and, most notably, achieves durable benefits (more than 2.5 years) for 15-20% of treated patients 7, 8 . Blockade of CTLA4 with antibody drugs is associated with a significant incidence of inflammatory toxicities, although most toxicities are readily managed with medical treatment.
The clinical results with ipilimumab illustrate how immunotherapy can induce long-lasting responses owing to the generation of anti-tumour immune memory. Although antibody treatment is typically
Oncogene addiction
A process by which a single mutated gene or signalling pathway drives tumour proliferation; inhibition of that gene or pathway results in rapid tumour response.
Vaccination in situ
As tumour cells die and release 'danger' molecules, tumour antigens are phagocytosed and presented by dendritic cells to prime anti-tumour immune responses.
Regulatory T (T Reg ) cells
A T cell subtype that releases suppressive cytokines and serves to silence immune responses.
Myeloid-derived suppressor cells
MDSCs. A myeloid cell subtype that silences responses of cytotoxic CD8 + T cells and helper CD4 + T cells while simultaneously promoting the formation of regulatory T cells.
Major histocompatibility complex
MHC. Proteins that are responsible for displaying varied peptide antigens on the cell surface.
completed within a few months, the stimulated immune response can accomplish disease control for extended periods. A dynamic host response might also underlie the unusual pattern of clinical response seen with ipilimumab, in which prolonged periods of stable disease or even an initial period of tumour growth before stabilization are sometimes observed 9 . Additionally, immune responses with ipilimumab can display an increase in breadth over time, diversifying reactivity to multiple tumour-associated antigens. Notwithstanding these advantages, an important limitation of ipilimumab is the fairly small proportion of patients who achieve clinical responses. This deficiency may at least partly reflect the potent immunosuppressive effects of wellestablished tumours, particularly given that many cancers are detected at a late stage when bulky lesions are already present.
This analysis of the strengths and weaknesses of targeted agents and immunotherapy suggests that the two approaches might have complementary roles in cancer treatment, and that combinatorial therapy could prove synergistic. Because targeted therapies can induce rapid tumour regressions, with a consequent decrease in tumour-associated immunosuppression, they may afford a favourable window for immunotherapy to achieve more potent cytotoxicity. Additionally, targeted therapies might potentiate anti-tumour immune responses by breaking 'oncogene addiction' , in turn triggering tumour cell senescence and facilitating tumour clearance by T cells 10, 11 . Moreover, the release of large amounts of antigenic debris on tumour cell death may contribute to the success of vaccination in situ, particularly if concurrent DC activation can be triggered. Thus, immunotherapy might consolidate the dramatic tumour responses that are achieved with targeted therapy into durable, long-lasting remissions in which sustained host immune responses targeting multiple cancer-associated antigens may reduce the risk of potentially lethal drug-resistant tumour cell clones.
In addition to tumour cell killing, targeted therapies may also directly modulate immune responses. For example, some targeted therapies attenuate the activities of specific immune cell populations that restrain cytotoxic T lymphocytes (CTLs), such as forkhead box P3 (FOXP3) + regulatory T (T Reg ) cells and myeloid-derived suppressor cells (MDSCs) 12, 13 . Other targeted agents augment tumour antigen presentation by DCs and enhance the priming of tumour-specific CTLs 14, 15 . Furthermore, some targeted therapies might sensitize tumour cells to immune-mediated destruction 16, 17 . The interplay of targeted agents and immunotherapy is complex, however, and parameters such as timing, dosage and sequence of administration are all likely to influence the overall anti-tumour effects and toxicity profiles of the combined treatments. A more complete understanding of the effect of targeted therapies on specific molecular pathways in immune cells should help to advance the integration of these agents with immunotherapy.
Activating an anti-tumour immune response
To date, the clinical evaluation of immunotherapy has primarily involved single agents that target individual steps in the host anti-tumour immune response. Because the induction, potency and persistence of host immune responses reflects the complex interplay of diverse immune cells with progressing tumours, monotherapies are unlikely to address the major mechanisms that impede anti-tumour immunity in all patients. Indeed, the generation of clinically effective anti-tumour responses probably requires the successful execution of several immune processes (FIG. 1) . Preclinical studies indicate that combinations of therapies that target distinct steps of anti-tumour immunity might be synergistic, resulting in stronger and more sustained responses that accomplish durable tumour destruction
.
To generate potent anti-tumour immunity, antigenpresenting cells, most notably DCs, must undertake a number of processes. First, they must capture tumour antigens, process them into major histocompatibility complex (MHC) class I and MHC class II pathways, and display the resulting peptide epitopes in an immunogenic context to stimulate CD8 + T cells and CD4 + T cells, respectively, and this usually occurs in a regional lymph node 18 . This process seems to be relatively inefficient during tumour formation, but can be effectively stimulated with a variety of cancer vaccination strategies. Second, tumour-specific T cells must differentiate into effector T cells, which requires a combination of signals from both the T cell receptor (TCR) -which establishes specificity -and several costimulatory molecules 19 . The TCR (and associated CD4 or CD8 molecules) engages peptide-MHC complexes that are presented on DCs; whereas, co-stimulatory signals are delivered through multiple transmembrane proteins of the B7 and tumour necrosis factor receptor (TNFR) families, as well as receptors for some cytokines, such as interleukin-12 (IL-12). In addition to the co-stimulatory molecule CD28, which binds CD80 (also known as B7-1) and CD86 (also known as B7-2) on DCs, other activating receptors that are currently under active study include 4-1BB (also known as CD137 and TNFRSF9), OX40 (also known as TNFRSF4) and glucocorticoid-induced TNFR-related protein (GITR; also known as TNFRSF18). Agonistic antibodies to these molecules can enhance co-stimulation to augment anti-tumour immunity [20] [21] [22] [23] .
Third, T cells must avoid negative regulatory signals (known as immune checkpoints) that dampen their activation or that induce tolerance programmes such as anergy or exhaustion 24 . In this regard, CTLA4 and programmed cell death protein 1 (PD1) are major negative co-stimulatory molecules that are expressed on activated T cells. Similar to ipilimumab, antibody blockade of PD1 amplifies T cell function and has demonstrated encouraging anti-tumour effects in initial clinical testing 25, 26 . Last, the induced antitumour immune response must be capable of overcoming diverse immunosuppressive networks within the tumour microenvironment, which may be driven by both soluble factors and regulatory cell populations. 
Immunomodulatory effects of targeted therapies
The molecular understanding of cancer biology has advanced substantially over the past two decades. Many investigations have uncovered crucial pathways that drive tumour growth and maintenance, yielding rationally designed drugs that can attenuate these circuits 3 . Interestingly, several of the targeted pathways are also involved in the development, activation, differentiation and function of immune cells. Thus, some of the targeted agents manifest important immunomodulatory properties. Similar to the more typical immunotherapies (described above), targeted agents may influence diverse aspects of the immune response, including bolstering tumour antigen presentation and T cell priming; enhancing T cell activation, effector function and differentiation; sensitizing tumour cells to killing by immune effector cells; and antagonizing tumour-mediated immunosuppression. These activities raise the intriguing possibility that some components of the anti-tumour efficacy of targeted therapies might involve the participation of the host immune system (TABLE 1) .
Targeted therapies boost antigen presentation
As mentioned above, DCs are crucial for priming tumourspecific T cells 18 . DCs express an array of Fc receptors that bind and internalize antibody-antigen immune complexes, which contributes to the activation and maturation of DCs 27 . Monoclonal antibodies facilitate the uptake of tumour antigens by DCs, which helps to stimulate the activation and expansion of tumour-specific CD4 + and CD8 + T cells (FIG. 2) . Trastuzumab and cetuximab are clinically efficacious monoclonal antibodies that are directed towards the tumour-associated receptor tyrosine kinases HER2 and EGFR, respectively 28 . In addition to attenuating oncogenic signalling, these antibodies augment tumour antigen presentation through the formation of immune complexes, which enhances the induction of
Box 1 | Combinatorial immunotherapy
Optimizing immunotherapy requires treatments that affect multiple aspects of the immune response. One immunotherapy combination is the use of cancer vaccines to generate anti-tumour T cells and immune checkpoint blockade to prevent T cell anergy. Cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) are two well-described co-inhibitory molecules that are expressed on T cells that decrease anti-tumour immune responses (reviewed elsewhere in this issue 128 ). A small trial combining autologous granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting tumour cell vaccines with CTLA4 blockade found increased inflammatory infiltrates and tumour regression 26 , suggesting that vaccine-induced anti-tumour T cells were present within the tumour but anergized owing to CTLA4 co-inhibition. Similarly, in a preclinical study combining vaccines and PD1 blockade, mice receiving combination therapy had increased overall survival and decreased tumour growth 25 . Additionally, combining blockade of multiple inhibitory pathways decreases T cell anergy and improves T cell responsiveness 103 . In one preclinical study, animals treated with cancer vaccines were found to have significantly higher overall survival if they were concurrently treated with antibodies to PD1 and CTLA4 compared with animals treated with vaccination and either antibody alone 103 .
A different strategy for overcoming T cell anergy is by providing an exogenous co-stimulatory signal while simultaneously blocking co-inhibitory signalling. 4-1BB is a co-stimulatory receptor that is expressed on activated T cells, and crosslinking 4-1BB with agonistic antibodies augments anti-tumour T cell function in many different mouse models [20] [21] [22] . In one study, combining CTLA4-blocking antibodies and 4-1BB-agonistic antibodies induced complete tumour regression in the combination treatment group; whereas, mice receiving either single agent alone had continued tumour growth 102 . Combinatorial therapy using an agonistic antibody to another co-stimulatory molecule, the glucocorticoid-induced TNFR-related protein (GITR), and CTLA4 blockade shows similar results 23 . These data suggest that combining agonistic antibodies delivering a co-stimulatory signal with antibodies blocking inhibitory signals promotes potent anti-tumour immunity. Additionally, the development of new combinatorial therapeutics for cancer immunology is ongoing, with multiple agents, such as bispecific T cell engagers (BiTEs) 104 , immunotoxins 105 and Fc-fusion proteins, entering clinical testing 106 . www.nature.com/reviews/cancer r e V i e W S tumour-specific T cells 29, 30 . In patients who received trastuzumab, a potent T cell response was correlated with improved clinical outcomes 31 . Animal models further established that the therapeutic efficacy of HER2 antibodies requires Fc receptors and CD8 + T cells in vivo; animals treated with these antibodies generated more tumour-specific T cells compared with controls 32 . These effects of monoclonal antibodies on antigen presentation suggest a potential synergy with therapeutic cancer vaccines. In a transgenic mouse model of breast cancer, mice that received a combination of HER2 antibodies and a cancer cell vaccine had significantly longer survival rates than those of either therapy alone 30 . The combined therapy increased the uptake of the cells from the cancer vaccine by DCs, enhanced the expression of co-stimulatory molecules such as CD40, CD80 and CD86 on the DCs and triggered greater tumourspecific T cell responses compared with either agent alone 33 . Consistent with these findings, a recent Phase I/II clinical trial of a HER2 peptide vaccine combined with trastuzumab showed that 69% of patients developed T cell immunity to tumour cells that expressed HER2, and Fc receptor-mediated opsonization also enhances the expression of co-stimulatory molecules such as CD40, CD80 and CD86 on the DC surface, promoting T cell activation. Janus kinase 2 (JAK2) inhibitors inhibit signal transducer and activator of transcription 3 (STAT3) signalling, an immunosuppressive pathway, which boosts expression of co-stimulatory molecules. mTOR and glycogen synthase kinase 3β (GSK3β) inhibitors drive T cells towards long-lived memory T cell phenotypes that generate a large pool of enduring anti-tumour T cells, even after completion of immunotherapies. b | Numerous therapies increase the expression of tumour antigens on the tumour cell surface, increasing T cell receptor (TCR) signalling and T cell activation. Inhibitor of apoptosis protein (IAP) inhibitors reinforce T cell signalling and provide exogenous co-stimulatory signals, which increases the production of inflammatory cytokines. PI3K inhibitors eliminate some pro-survival signals, increasing tumour cell lysis to perforin and granzymes released from cytotoxic T lymphocytes (CTLs). Therapies also increase expression of natural killer group 2, member D (NKG2D) ligands, which serve as additional co-stimulatory molecules for CTLs, as well as activators of natural killer (NK) cells, which also kill tumour cell targets through the perforin-granzyme pathway. EGFR, epidermal growth factor receptor; HDAC, histone deacetylase; HSP90, heat shock protein 90; MHC, major histocompatibility complex. r e V i e W S 242 | APRIL 2012 | VOLUME 12 www.nature.com/reviews/cancer r e V i e W S
Epitope spreading
After peptide vaccination, T cells are generated that respond to peptides that were not in the original vaccine formulation, indicating that a secondary round of T cell priming has occurred with antigens taken directly from tumour cells.
T helper 1
(T H 1). A helper T cell response that is characterized by interferon-γ (IFNγ) production and stimulation of CD8 + cytotoxic T cells.
Natural killer (NK) cells
A cytotoxic cell of the innate immune system that does not recognize target cells in an antigen-specific manner and kills its targets using similar mechanisms to those of the cytotoxic T lymphocyte.
Opsonization
The phagocytosis of opsonized antigens, most commonly by antibodies and/or complement, from the external environment by dendritic cells or by other antigen-presenting cells. 
Memory T cells
T cells that have undergone antigenic stimulation at least once and that are capable of rapidly responding to additional antigen encounters.
that 70% of these patients manifested epitope spreading to target HER2 peptides that were not represented in the vaccine, as well as other tumour-associated antigens 34 . These findings suggest that vaccine-activated T cells might release cytokines that facilitate DC trafficking, phagocytosis, activation and priming of additional tumour-specific T cells. Augmented T cell reactivity, as measured using an enzyme-linked immunosorbent spot (ELISPOT) assay, also correlated with increased survival.
Because HER2 antibody therapy boosts T cell priming, combinatorial strategies with other approaches to enhance T cell activation seem to be promising. In experimental models, the combination of HER2 antibodies with either blocking PD1 antibodies or agonistic 4-1BB antibodies accomplished greater tumour growth control than either monotherapy 35 . The combination of HER2 antibodies with systemic IL-12, a T helper 1 (T H 1)-polarizing cytokine that activates CTLs and natural killer (NK) cells, similarly decreased tumour progression and increased tumour necrosis compared with either treatment alone 36 . In accordance with these results, a Phase I clinical trial combining systemic IL-12 with trastuzumab and paclitaxel showed enhanced production of interferon-γ (IFNγ) -which is a pro-inflammatory cytokine that activates many immune cell types -as well as increases in NK cell activation; both of these effects were correlated with clinical responses 37 . The EGFR antibody cetuximab also facilitates DC priming to augment anti-tumour immunity 29 . In an in vitro study using colon cancer cell lines, cetuximab promoted DC opsonization of tumour cells, and associated DC maturation with increased expression of MHC class II molecules, CD40, CD80 and CD86. DCs incubated with tumour cells and cetuximab more effectively primed tumour-specific T cells than DCs that were incubated with tumour cells alone. Additionally, cetuximab facilitates NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) 38 and complement-dependent cytotoxicity (CDC) 39, 40 , which may further enhance tumour cell killing. Partly on the basis of these results, cetuximab is currently being evaluated in a Phase II clinical trial in combination with an allogeneic pancreatic cancer cell vaccine that secretes granulocyte-macrophage colony-stimulating factor (GM-CSF), which is an immune-stimulatory cytokine (NCT00305760).
Analogous to monoclonal antibodies, small-molecule kinase inhibitors have important effects on DCs and antigen presentation. Janus kinase 2 (JAK2) inhibitors not only interfere with tumour cell survival signals, but they also augment DC function through the blockade of signal transducer and activator of transcription 3 (STAT3) signalling, which is a key immunosuppressive pathway 41 . DCs treated with JAK2 inhibitors in vitro show increased MHC class II molecule, CD40 and CD86 expression 14 , whereas, ex vivo DCs isolated from tumour-bearing mice treated with a JAK2 inhibitor had enhanced induction of allogeneic CD4 + T cell responses 15 . JAK2 inhibitors may elicit the accumulation of mature DCs and decrease the number of immature DCs, which typically trigger dysfunctional or suppressive T cells 14 . As a consequence of these stimulatory effects, combined treatment with a JAK2 inhibitor and a DC vaccine accomplished increased antitumour effects than either monotherapy 15 . The mechanisms by which targeted therapies modulate DC function are addressed in more detail below.
Targeted therapies and T cell differentiation Although DCs are crucial for priming the initial antitumour T cell response, maintaining the activation of T cells and promoting their differentiation into memory T cells is important for achieving a long-lasting anti-tumour immune response 42 , and this is also correlated with prolonged overall survival in patients 43, 44 . Many targeted therapies modulate T cell proliferation and responsiveness to tumour antigens, which makes them attractive candidates for potential synergy with immunotherapy (FIG. 2) .
The mTOR pathway has been well characterized in the regulation of multiple immune cells, and rapamycin (an inhibitor of mTOR) has been used clinically as an immunosuppressant for more than a decade 45 . However, recent evidence suggests that under some conditions mTOR inhibitors may have a stimulatory effect on T cells 46 . In a lymphocytic choriomeningitis virus (LCMV) mouse model of acute viral infection, animals treated with rapamycin showed an increased early expansion of CD8 + virus-specific T cells, increased effector-to-memory T cell differentiation, and enhanced re-activation, function and survival of memory T cells 46 . Comparable responses were obtained in mice using a non-replicating virus vaccine and in non-human primates using a live-attenuated virus vaccine 46 , suggesting a novel therapeutic indication for mTOR inhibitors.
On the basis of these findings, recent investigations have evaluated the use of mTOR inhibitors in the context of cancer immunotherapy. The combination of temsirolimus (a derivative of rapamycin) and cancer vaccination with an HSP90 adjuvant and either of two tumour-specific proteins, gp100 (also known as PMEL) and carbonic anhydrase 9 (CA9), strongly inhibited tumour growth in the B16 melanoma and RENCA renal cell carcinoma mouse models, respectively 47 . Notably, animals that received temsirolimus and the vaccines had significantly more tumour-specific T cells than animals receiving either treatment alone. In another mouse model of metastatic renal cancer, the mTOR inhibitor AZD8055 combined with an agonistic CD40 antibody triggered greater intra-tumoural CD8 + T cell, DC and macrophage infiltration and superior disease control compared with either monotherapy 48 . However, on a cautionary note, this synergy was not observed when a second mTOR inhibitor (rapamycin) was combined with the agonistic CD40 antibody, suggesting that alterations in drug design or perhaps dosing might result in different immunogenic properties.
In addition to these stimulatory actions on effector and memory T cells, mTOR inhibitors affect FOXP3 + T Reg cells 49, 50 . mTOR inhibitors may expand the population of T Reg cells when given before an immune stimulus, such as a vaccine 49 , whereas continuous mTOR inhibition after immune stimulation may impede both T Reg cells and effector T cells equally 50 . Furthermore, release of mTOR inhibition after tonic blockade may cause a rapid rebound in the T Reg cell population, which skews r e V i e W S NATURE REVIEWS | CANCER VOLUME 12 | APRIL 2012 | 243
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Central memory T (T CM ) cells
Long-lived memory T cells that reside in peripheral blood, lymph nodes and spleen that are capable of undergoing rapid differentiation into effector T cells on antigenic stimulation.
Adoptive transfer
The infusion of cells into animals or patients that have been taken directly from another source or expanded and modified ex vivo.
Lytic pathway
The release of cytotoxic molecules such as perforin and granzymes from cytotoxic T lymphocytes to kill their cognate targets.
Unfolded protein response
A stress response in the endoplasmic reticulum that is triggered by the accumulation of misfolded proteins that initially results in increased protein chaperone synthesis and decreased total protein synthesis in an attempt to remove the misfolded proteins. If misfolded proteins persist, continued activation of this pathway ultimately results in apoptosis.
the ratio of effector T cells to T Reg cells towards immunosuppression. These results indicate that the timing, dose, sequence of administration and cycling of mTOR inhibitors with immunotherapy need to be carefully investigated to maximize anti-tumour effects. WNT signalling is another important oncogenic pathway that can affect T cell differentiation. One important component of the WNT signalling pathway is glycogen synthase kinase 3β (GSK3β). Because this protein has been implicated in promoting tumour growth in many gastrointestinal malignancies, inhibitors of GSK3β may thus decrease tumour cell viability in vitro and in vivo 51, 52 . Interestingly, a recent study linked the WNT pathway to memory T cell differentiation 53 . Transgenic T cells that were stimulated with peptide-loaded DCs and exposed to the GSK3β inhibitor TWS119 differentiated into a 'stem-cell'-like memory phenotype, called T SCM cells. These T SCM cells are distinct from classical central memory T (T CM ) cells and effector memory T (T EM ) cells. T SCM cells manifested low basal rates of division, but were selfrenewing and promptly differentiated into T CM and T EM cells on stimulation. After adoptive transfer into tumourbearing mice, T SCM cells mediated potent tumour regression; whereas, transferred T EM or T CM cells showed less anti-tumour activity, probably owing to the inferior survival of these cells 53 . Given the importance of generating long-lasting T cells to achieve durable tumour control, GSK3β inhibitors should be further investigated in combination with immunotherapies.
Targeted therapies may also function as co-stimulatory agents, analogous to agonistic antibodies directed against 4-1BB, GITR, OX40 and other TNFR superfamily members that are expressed on T cells. Of particular interest in this regard are antagonists of the inhibitor of apoptosis proteins (IAPs). IAP inhibitors were originally developed to counteract the role of IAPs in blocking caspase activation, thereby sensitizing cancer cells to death stimuli 54 . Unexpectedly, IAP inhibitors were found to mimic co-stimulatory signalling in T cells 55 . Although these compounds had minimal effects on resting T cells, they dramatically enhanced T cell activation on TCR engagement, resulting in increased proliferation and cytokine production. These stimulatory effects involved triggering non-canonical nuclear factor-κB (NF-κB) signalling, as cIAP1 (also known as BIRC2) and cIAP2 (also known as BIRC3) are major negative regulators of NF-κB-inducing kinase (NIK; also known as MAP3K14) 56 . In a preclinical mouse model of melanoma, the combination of IAP antagonists and tumour cell vaccines evoked a greater reduction in tumour growth and stronger anti-tumour T cell responses compared with either mono therapy 55 . These findings suggest that IAP inhibitors might potentiate the effects of vaccination and possibly of other T cell immunotherapies.
Sensitization to immune-mediated destruction
Although T cells have the capacity to efficiently kill tumour cells, the execution of the lytic pathway requires the engagement of CTLs with their cognate tumour targets. Consequently, tumour cells may develop escape mechanisms to evade T cell-mediated killing, such as lowering the expression of MHC class I molecules to avoid detection or increasing anti-apoptotic proteins to resist cytotoxic programmes 57 . Targeted agents may counteract these strategies to improve immune-mediated tumour destruction (FIG. 3) .
Bortezomib is a potent inhibitor of the proteasome that is approved for use in multiple myeloma, and treatment with this drug compromises tumour cell viability, at least in part, through the accumulation of misfolded proteins that in turn engage the unfolded protein response 58 .
In addition to these cell-autonomous effects, bortezomib modulates the sensitivity of tumour cells to immune attack. Because the proteasome generates peptide epitopes for MHC class I molecules, bortezomib may decrease peptide loading and MHC class I expression, rendering tumour cells more susceptible to killing by NK cells, the activation of which is normally blocked by MHC class I molecules 59 . Bortezomib can also increase tumour cell surface expression of FAS (also known as TNFRSF6) and the TNF-related apoptosis-inducing ligand (TRAIL) receptor DR5 (also known as TNFRSF10B), which further augments NK cell cytotoxicity 60 . Moreover, bortezomib may sensitize tumour cells to lysis through enhanced expression of NOXA (also known as PMAIP1) 16 , a BH3 protein that sequesters potent anti-apoptotic proteins such as myeloid cell leukaemia sequence 1 (MCL1) 61 . Finally, bortezomib may augment the baseline activity of granzyme B and caspase 8 in tumour cells 16 , which could provide additional sensitization towards apoptosis.
In a preclinical model of human papilloma virus (HPV)-induced disease, the combination of bortezomib and an HPV E7-based vaccine achieved prolonged stable disease, in contrast to either monotherapy, which displayed minimal effects 62 . The increased survival correlated with enhanced sensitivity of the bortezomib-treated tumour cells to killing by E7-specific CTLs. Splenocytes from mice that received the combination therapy also showed increased E7-specific CTL responses compared with control-treated animals, suggesting that bortezomib might also augment T cell priming and activation.
Inhibitors of the PI3K-AKT pathway are a second class of targeted agents that sensitize tumour cells to immunemediated destruction, in part through compromising anti-apoptotic signalling 17, 63 . Tumour cells in which AKT can be inducibly expressed manifested enhanced resistance to T cell killing on AKT activation compared with the non-induced cells, and this involved an increase in MCL1 expression 17 . In complementary work, a tumour cell line that was selected for resistance to immunotherapy upregulated AKT compared with sensitive wild-type cells, and this was associated with increased levels of cIAP1 and cIAP2, BCL-2 and BCL-X L (also known as BCL2L1) 63 . AKT inhibitors diminished the expression of these antiapoptotic proteins, sensitizing the tumour cells to T cell killing in vivo. Together, these findings suggest that PI3K-AKT inhibitors might prove synergistic with some immunotherapies, although the effect of these agents on T cell and NK cell function will need to be carefully evaluated.
Another approach to boost T cell-mediated tumour cell killing is to increase the levels of tumour antigens. In this context, an unexpected link between BRAF inhibitors and the expression of melanoma T cell antigens was recently uncovered 64 . In malignant melanoma, the BRAF-V600E mutant (present in approximately 50% of patients with metastatic disease) promotes constitutive activation of the MAPK pathway, which contributes to tumour growth. Vemurafenib, a specific BRAF inhibitor that was recently approved for therapy of BRAF-mutant melanomas 65 , enhances the expression of well-defined T cell target antigens, including gp100, tyrosinase-related protein 1 (TYRP1), TYRP2 and melanoma antigen recognized by T cells 1 (MART1) 64 . Consistent with these results, MART1-and gp100-specific T cells showed increased responsiveness and IFNγ production against melanoma cells that were treated with BRAF inhibitors compared with controls. The BRAF inhibitors did not seem to interfere with T cell differentiation and activation, at least in vitro 64 ; MEK inhibitors, which might be used in combination with vemurafenib as a strategy to reduce drug resistance that is mediated through MEK activation, require further study to assess their effects on T cell function and melanoma antigen expression.
Heat shock protein 90 (HSP90) inhibitors provide an additional strategy for augmenting tumour cell antigen expression. HSP90 is a major chaperone that helps to maintain the correct folding of multiple client proteins, including several oncoproteins 66 . HSP90 inhibitors promote the accumulation of misfolded proteins, which may be digested and processed into short peptides and then loaded onto MHC class I molecules 67 . These effects of HSP90 inhibitors on antigen presentation increase tumour cell sensitivity to CTL-mediated lysis in vitro 68 and to adoptive T cell transfer in vivo 67 . In experimental models, HSP90 inhibitors were also effectively combined with DNA vaccines to decrease tumour growth and improve survival; these effects were abrogated on treatment with an antibody that depletes CD8 + T cells, which establishes a crucial role for this cell type in tumour destruction 67 . HSP90 inhibitors also augment the expression of 'stress molecules' , such as natural killer group 2, member D (NKG2D) ligands, in both Hodgkin's lymphoma 69 and multiple myeloma 70 . These surface proteins may directly activate NK cells and co-stimulate CD8 + T cells, which is a major mechanism for protective anti-tumour immunity 71 . Histone deacetylase (HDAC) inhibitors similarly promote NKG2D ligand expression, suggesting that these drugs might sensitize tumour cells to immune cell killing through a shared mechanism 72, 73 .
Dampening tumour-induced immunosuppression
A major impediment to the therapeutic efficacy of antitumour T cells is the immunosuppressive tumour microenvironment 74 . Diverse mechanisms operate, including the production of inhibitory cytokines such as IL-10 and transforming growth factor-β (TGFβ); the expression of negative co-stimulatory ligands such as programmed cell death 1 ligand 1 (PDL1); and the presence of regulatory lymphocyte and myeloid cell populations. The identification of agents that attenuate these suppressive networks might substantially increase the efficacy of immunotherapies (FIG. 3) .
Vascular endothelial growth factor A (VEGFA) is best known for its effects on angiogenesis 75 , but this cytokine also manifests potent immunoregulatory actions. These actions include blocking the maturation of DCs and promoting the expansion of MDSCs 76 . The addition of bevacizumab, a monoclonal antibody that neutralizes VEGF, during DC differentiation enhanced the induction of T cell responses. By contrast, bevacizumab had limited effects when added to matured DCs, suggesting that there is a specific window during DC development in which VEGF functions. In accordance with these results, DCs loaded with multiple myeloma cell lysates (containing VEGFA) displayed lower levels of co-stimulatory molecules and a reduced ability to stimulate T cells compared with unloaded DCs, whereas, bevacizumab diminished these suppressive effects 77 . VEGFA blockade augmented NF-κB activation but blocked STAT3 signalling, resulting in increased IL-12 levels but decreased IL-10 levels. In the B16 melanoma model, a VEGFA antibody combined with adoptive T cell transfer intensified tumour infiltration, decreased tumour growth and prolonged survival compared with either monotherapy 78 . The effects of VEGFA blockade were greater if animals were pretreated with the antibody before T cell transfer, which perhaps reflects a more efficient localization of transferred T cells to the tumour microenvironment.
Small-molecule inhibitors targeting VEGF receptor (VEGFR) signalling have comparable immunostimulatory effects. In a mouse model of colon cancer, the administration of sunitinib, which is a multi-tyrosine kinase inhibitor that blocks VEGFR function, decreased the numbers and function of MDSCs and T Reg cells both systemically and in the tumour microenvironment 79 . Consequently, sunitinib augmented tumour-infiltrating T cell IFNγ production and cytotoxicity, but diminished the expression of CTLA4, PD1 and PDL1. Furthermore, the combination of sunitinib with an agonistic 4-1BB antibody and IL-12 resulted in improved overall survival compared with regimens containing only one or two of these agents. In a B16 melanoma model, the combination of sunitinib and a DC vaccine similarly enhanced survival compared with either agent alone 80 . Sunitinib was most effective when administered concurrently with vaccination, suggesting that VEGF blockade with small molecules, analogous to antibodies, may be most important during the initial DC priming of anti-tumour T cells. However, one cautionary note is that seemingly related small-molecule inhibitors might not have identical activities; sorafenib is a multikinase inhibitor that targets VEGFR, but this agent seems to be immunosuppressive, which is possibly related to its inhibitory effects on MEK signalling 81 . In addition to inhibiting VEGFR function, sunitinib may block STAT3 activation, which is another major immunosuppressive pathway 41 . In the B16 melanoma model, animals with a T cell-specific STAT3-null mutation had enhanced overall survival and increased numbers of tumour-specific T cells compared with wild-type animals 82 . In a RENCA renal cancer model, mice treated with sunitinib and adoptive T cell transfer showed better responses compared with either monotherapy. However, if STAT3-null T cells were transferred, sunitinib had no additional therapeutic effects, which suggests that STAT3 is the major target in this system 82 . Sunitinib-mediated STAT3 inhibition similarly enhanced the therapeutic effects of adoptive T cell transfer and vaccination in a mouse model of hepatocellular carcinoma 83 . Because JAK2 phosphorylates STAT3 in many signalling cascades, treatment with JAK2 inhibitors might also be an effective strategy for dampening STAT3 activation 15 .
Comparable to the investigations with sunitinib, tumourbearing mice that were treated with JAK2 inhibitors displayed increased DC maturation and T cell polarization towards a T H 1 cell phenotype, with enhanced IL-2 and IFNγ production 15 . JAK2 inhibitors augment the therapeutic effects of DC vaccination 15 and decrease tumour cell PDL1 expression at the level of transcription 84 . Another immunosuppressive pathway that is mediated by tumour-associated myeloid cells involves indoleamine-pyrrole 2,3-dioxygenase (IDO; also known as IDO1)-catalysed degradation of tryptophan, an amino acid that is required for optimal T cell function, into metabolites that are directly toxic to T cells and important for immune tolerance 85 . Unexpectedly, imatinib was found to decrease IDO expression in myeloid cells 86 . In a mouse model of gastrointestinal stromal tumours, imatinib led to an increased ratio of intra-tumoural CTLs to T Reg cells, which promotes tumour destruction. Concurrent administration of imatinib and CTLA4 antibodies resulted in greater increases in IFNγ production and cytotoxicity of CD8 + T cells compared with either agent alone. Imatinib might also have direct inhibitory effects on T Reg cells, decreasing their number and immuno suppressive capacity 87 . Notably, the combination of imatinib and a DC vaccine in a BCR-ABL -lymphoma model resulted in decreased numbers of T Reg cells, fewer metastases and increased T cell-derived IFNγ production compared with either monotherapy. Given the potent effects of imatinib in this BCR-ABL -model, further studies should be undertaken to determine whether this targeted therapy might be used more broadly as a component of combination immunotherapy.
Tumour-promoting inflammatory responses are an additional major component of the tumour microenvironment 88 . Myeloid cells play a central part in these responses and, in a PI3K catalytic subunit-γ (p110γ)-dependent r e V i e W S 246 | APRIL 2012 | VOLUME 12 www.nature.com/reviews/cancer r e V i e W S manner, they respond to tumour-derived factors, infiltrate the lesions and release pro-tumorigenic cytokines 89 . Accordingly, genetic and pharmacological inhibition of p110γ decreased myeloid cell infiltration, with a concomitant reduction in tumour growth and metastases. Because the p110γ isoform is predominantly expressed in immune cells and not in tumour cells, the primary target for these inhibitors seems to be the host. A further link between oncogenic pathways and immunoregulation involves mutant BRAF, which drives the secretion of suppressive cytokines such as IL-10 and VEGFA from melanoma cells 90 . The inhibitor of mutant BRAF, vemurafenib, blocks these effects and thereby increases DC responsiveness, which indicates that targeted therapies can directly antagonize tumour-derived suppressive factors.
This Review focuses on targeted agents, but conventional cytotoxic chemotherapy also affects many aspects of the anti-tumour immune response
. For example, chemotherapy triggers the release of 'danger' molecules from tumour cells, such as high mobility group protein B1 (HMGB1) and ATP, increasing DC tumour antigen presentation and maturation 91 . Chemotherapy may sensitize tumour cells to T cell-mediated killing by increasing the expression of death receptors, such as DR5, and co-stimulatory molecules, such as NKG2D ligands 92 . Furthermore, chemotherapy may kill T Reg cells and MDSCs, allowing the partial amelioration of tumourdriven systemic immunosuppression 93, 94 . Interestingly, external beam radiation therapy (XRT) seems to have similar effects, as it facilitates the release of danger signals such as HMGB1, and also sensitizes tumour cells by increasing the expression of FAS and NKG2D ligands 95 . Given the properties of both of these therapeutic modalities, incorporating immunotherapeutic strategies into conventional treatment protocols provides many opportunities for potential synergies.
Challenges for combination strategies Targeted therapies offer great promise for boosting responses with immunotherapy, but the appropriate timing, dosage and sequencing of these agents will probably be crucial to the success of combinatorial approaches. In this context, some targeted therapies with immunostimulatory potential also display immuno suppressive activities. For example, although HSP90 inhibitors may increase CTL-mediated tumour cell lysis through enhanced antigen presentation on MHC class I molecules, they may also decrease some macrophage and DC functions 96, 97 . Similarly, the mTOR inhibitor temsirolimus may diminish the ability of DCs to prime tumour-specific T cells 47 ; whereas, bortezomib 98, 99 and HDAC inhibitors 100 may impede some NK cell actions.
A second key issue for combinatorial therapies is whether intensified anti-tumour effects can be achieved without a corresponding increase in serious toxicities. The major adverse events with immunomodulatory agents such as ipilumimab and PD1 antibodies are inflammatory pathologies, and combining treatments that affect different steps in an immune response might be anticipated to increase the likelihood of these side effects. Although preclinical studies investigating these toxicities are clearly warranted, they may not fully predict the range of pathology that is observed in humans; for example, inflammation in the pituitary gland (hypophysitis) is a fairly common side effect of ipilimumab, but it was not anticipated from experimental studies in mice 101 . Unexpectedly, some preclinical experiments raise the possibility that particular combination treatments, such as CTLA4 blockade and a 4-1BB agonist antibody, might diminish, rather than exacerbate, inflammatory toxicities 102 .
Box 2 | Conventional cytotoxic therapies in conjunction with immunotherapies
Numerous lines of evidence suggest that anti-tumour immunity is crucial for clinical responses towards conventional cancer treatments. For example, in a broad array of tumour types, patients with denser T cell infiltrates within tumours have a better clinical response to cytotoxic therapy compared with patients with smaller infiltrates 92, 107, 108 . In animal models, tumours regress more quickly to chemotherapy in immunocompetent animals compared with immunodeficient ones 92 . Surprisingly, although they were initially thought to be immunosuppressive, anticancer therapies can promote anti-tumour immunity. Some cytotoxic therapies, such as anthracyclines or ionizing radiation, promote 'immunogenic cell death', which includes the release of 'danger' molecules from tumour cells such as calreticulin, high mobility group protein B1 (HMGB1) and ATP (reviewed in REF. 91 ). These danger molecules polarize dendritic cells (DCs) towards a pro-inflammatory phenotype and increase priming towards T helper 1 (T H 1) anti-tumour T cells and away from regulatory T (T Reg ) cells. Additionally, some chemotherapies such as cyclophosphamide are directly toxic to immunosuppressive T Reg cells, and combining low-dose cyclophosphamide with tumour vaccines induces anti-tumour immunity in animal models 109 . Similarly, gemcitabine 93 and 5-fluorouracil (5-FU) 94 both selectively kill myeloid-derived suppressor cells (MDSCs) in vitro and in vivo, and animal models show that gemcitabine substantially increases the activity of immunotherapy when the two are given in combination. Surgical removal of primary tumour masses has also been shown to reverse tumour-derived immunosuppression 110 , which suggests that immunotherapies may have an even greater potency in adjuvant settings than in first-line therapy.
Numerous clinical trials are currently examining combinatorial strategies with immunotherapy and chemotherapy. In metastatic pancreatic adenocarcinoma, patients receiving gemcitabine and a DC vaccine had a median survival of 360 days 111 , a substantial prolongation compared with other cohorts treated with chemotherapy alone; in metastatic non-small-cell lung cancer combining a pox-virus-based interleukin-2 (IL-2) and mucin 1 (MUC1) immunotherapy with chemotherapy found a trend towards increased progression-free survival at 6 months 112 ; and in melanoma, combining cytotoxic T lymphocyte-associated antigen 4 (CTLA4) blockade with standard chemotherapy increased overall survival in a recent Phase III trial 7 . r e V i e W S NATURE REVIEWS | CANCER VOLUME 12 | APRIL 2012 | 247 The optimal timing and sequence of particular combinations of targeted agents and immunotherapy will need to be determined experimentally, but some guidance might be provided through considering the stage of immune response that is most likely to be affected (FIG. 4) . Broadly speaking, different therapies affect one of four areas of immune activation: DC presentation and T cell priming, T cell activation and anti-tumour effector functions, T cell differentiation into memory T cells, and tumour microenvironment antagonism.
Targeted therapies affecting DC priming might be given first, pretreating a patient before any immunotherapies, such as vaccination or adoptive T cell transfer, and then continued throughout the treatment course. This might skew the actions of DCs towards promoting T cell effector responses rather than promoting T Reg cells. For example, initiating sunitinib treatment before tumour vaccination yielded superior anti-tumour responses compared with concurrent administration; by contrast, cycling of sunitinib (4 weeks on and 2 weeks off) favoured the accumulation of MDSCs and T Reg cells in the off period, which perhaps reflects a rebound effect of unopposed VEGFA 12 . Pretreatment with monoclonal antibodies such as cetuximab or trastuzumab may similarly prove favourable, in this case through the enhanced phagocytosis of tumour antigens by DCs, which might promote DC maturation and priming 29, 33 . Additionally, agents that could antagonize DC function, such as HSP90 inhibitors 96 or sorafenib 81 , might be avoided at this time to maximize tumour-specific T cell priming.
Targeted therapies that augment T cell differentiation, such as GSK3β or mTOR inhibitors, might be administered after vaccination to promote the induction of memory T cells. Relatively short courses should be delivered though, as GSK3β inhibitors may block T SCM cell differentiation into effector T cells 53 , and mTOR inhibitors may prevent maximal T cell proliferation 47 . Immunostimulatory agents, such as antibodies that block Figure 4 | Crucial variables in combining targeted agents and immunotherapy. a | Immune responses against tumours occur in a step-wise manner. First, dendritic cells (DCs) must capture tumour antigens and present them to naive T cells under inflammatory conditions. Naive T cells then differentiate into effector T cells, which may take up to 1 week, before leaving the lymph node and entering the blood. At this time, some T cells further differentiate into long-lived memory T cells, which provide a pool of renewable anti-tumour T cells for an extended period after immunotherapy has ceased. Once in the periphery, tumour cells activate T cells, causing them to secrete inflammatory cytokines and/or cytotoxic granules. Throughout this process, T cells must overcome tumour-derived immunosuppression from myeloid-derived suppressor cells (MDSCs), regulatory T (T Reg ) cells and tumour cell-secreted suppressive molecules. b | Drugs modulating each of these areas should be delivered just before, as well as during, the respective crucial steps of immune maturation. Therapies boosting DC antigen presentation and initial T cell priming should be delivered before vaccines and continued through initial T cell priming. Agents promoting T cell memory formation should be given during T cell priming and then discontinued after differentiation is complete in order to avoid deleterious effects on effector function. Therapies enhancing T cell function and tumour cell lysis should be given after T cell priming is complete and continued throughout treatment to maximize effector function. Tumour-derived immunosuppression constantly antagonizes anti-tumour immune responses; accordingly, therapies that are designed to mitigate this should be given before vaccination and continued throughout treatment. 5-FU, 5-fluorouracil; CTL, cytotoxic T lymphocyte; GSK3β, glycogen synthase kinase 3β; HDAC, histone deacetylase; HSP90, heat shock protein 90; IAP, inhibitor of apoptosis protein; JAK2, janus kinase 2; mAbs, monoclonal antibodies.
immune checkpoint activation, agonistic co-stimulatory antibodies, and IAP inhibitors might be given after T cell priming and continued for a period thereafter (perhaps intermittently) to maintain effector T cell activation and prevent exhaustion.
Finally, targeted therapies that antagonize the immuno suppressive tumour microenvironment might find broad applicability, from preceding tumour vaccination through to treatment consolidation. Imatinib (which inhibits IDO), sunitinib (which antagonizes MDSCs and T Reg cells), cyclophosphamide (which kills T Reg cells), gemcitabine and 5-fluorouracil (5-FU), which both kill MDSCs, and p110γ inhibitors (which eliminate tumour-promoting inflammation) might be in this category, although a potential effect on T cell effector function needs to be carefully investigated.
Some of these principles are being tested in a recently initiated Phase I/II clinical trial that combines the mutant BRAF inhibitor vemurafenib with the immune checkpoint-blocking antibody ipilimumab in patients with metastatic melanoma (NCT01400451). This important study aims to convert the frequent tumour regressions that are achieved with vemurafenib into long-lasting clinical responses through the induction of a potent immunological memory. The abilities of vemurafenib to increase CTL recognition of tumour cells 64 and to decrease tumour immunosuppression 90 might amplify the capacity of CTLA4 blockade to boost T cell responses and prevent anergy. This trial will both evaluate the safety and tolerability of the combination therapy and provide a preliminary assessment of overall survival. Given the complementary modes of achieving tumour control with the two modalities, the patterns of clinical response will be of particular interest. This combinatorial strategy shows great potential based on mechanistic considerations, and will probably establish a paradigm for many similar studies to follow.
Conclusions
The discovery of crucial molecular pathways that promote tumour growth and maintenance together with the development of drugs that specifically inhibit these pathways has ushered in a new era of cancer medicine. Analogously, an improved understanding of the mechanisms of protective anti-tumour immunity and the translation of these concepts into efficacious immunotherapies that prolong patient survival has validated the long-standing idea that immunity plays an important part in cancer pathogenesis. The complementary modes of action of these two promising modalities suggest intriguing possibilities for therapeutic synergy with combination treatment. A strong foundation has been established to advance the crafting of both preclinical and early stage patient investigations to determine the best ways to integrate targeted agents and immunotherapy.
